Although the type of hepatic artery revascularization technique is known to have an impact on patency rates, independent perioperative risk factors on patient outcomes are poorly defined. All consecutive adult patients undergoing cadaveric liver transplantation (n 5 361) from July 2007 to June 2016 in a single institution were analyzed. Primary outcomes were early (<30 days) hepatic artery occlusion and primary hepatic artery patency rate. A multivariate model was used to identify independent risk factors for occlusion and the need of arterial conduit, as well as their impact on graft and patient survival. Arterial revascularization without additional reconstruction (end-to-end arterial anastomosis [AA]) was performed in 77% (n 5 279), arterial reconstruction (AR) in 15% (n 5 53), and aortohepatic conduit (AHC) in 8% (n 5 29) of patients. AHC had the highest mean intraoperative flow (275 mL/minute; P 5 0.02) compared with AA (250 mL/minute) and AR (200 mL/minute; P 5 0.02). There were 43 recipients (12%) who had an occlusive event with successful revascularization in 20 (47%) recipients. One-year primary patency rates of AA, AR, and AHC were 97%, 88%, and 74%, respectively. Aortic calcification had an impact on early occlusion. AR (odds ratio [OR], 3.68; 95% confidence interval [CI], 1.26-10.75; P 5 0.02) and AHC (OR, 6.21; 95% CI, 2.02-18.87; P 5 0.001) were independent risk factors for early occlusion. Dyslipidemia additionally independently contributed to early occlusion (OR, 2.74; 95% CI, 0.96-7.87; P 5 0.06). The 1-and 5-year graft survival rates were 83% and 70% for AA, 75% and 69% for AR, and 59% and 50% for AHC (P 5 0.004), respectively. In conclusion, arterial patency is primarily determined by the type of vascular reconstruction rather than patient or disease characteristics. The preoperative lipid status is an independent risk factor for early occlusion, whereas overall occlusion is only based on the performed vascular reconstruction, which is also associated with reduced graft and patient survival.
Liver transplantation (LT) is the most effective treatment for acute liver failure and end-stage liver disease.
(1) Although LT became a lifesaving procedure for numerous patients over the past 60 years, it is still associated with high morbidity, particularly in the early postoperative course. (2) (3) (4) (5) Vascular, notably arterial, complications have a strong impact on graft function, liver necrosis, or ischemic cholangiopathy. (2, 6, 7) These conditions therefore compromise patient and graft survival, and they are associated with a high retransplantation rate. (6, 8) The incidence of hepatic arterial occlusion ranges from 4% to 9% (8) (9) (10) requiring a second liver transplant in over 50% of patients. (2, 6) Typically, an end-to-end anastomosis of the hepatic artery is performed. In some circumstances, back-table reconstruction of the artery or the use of an aortohepatic conduit (AHC) is necessary to provide arterialization of the graft.
higher mortality and graft loss. (11, 12) Nevertheless, only a few studies have investigated the impact of the arterial reconstruction (AR) technique on arterial occlusion. (7, 8, 11) Furthermore, the influence of recipient characteristics, especially cardiovascular risk factors, on arterial occlusion are poorly defined.
Therefore, we analyzed the outcome of different types of arterial graft vascularization, their impact on arterial occlusion, and the role of independent perioperative donor and recipient risk factors within the same cohort.
Patients and Methods

STUDY DESIGN
From July 1, 2007 to June 30, 2016 , all adult patients (aged 18 years) who underwent cadaveric LT at the University Hospital Zurich were identified from a prospective transplant database. The main objective of the study was to conduct an outcome and risk analysis for primary arterial patency after LT based on the performed AR technique. Therefore, the cohort was divided into 3 groups based on the type of the hepatic artery revascularization technique such as end-to-end arterial anastomosis (AA) or AR of the donor hepatic artery as well as the use of an AHC. The AR group included any type of complex back-table AR of an aberrant or replaced left or right hepatic artery as well as any other type of arterial variants. The arterial donor anatomy was classified according to Hiatt et al. (13) LT with donor organs from both donation after brain death (DBD) and donation after circulatory death (DCD; Maastricht 3 criteria) were included in the study. Patients who experienced intraoperative death or underwent split, living donor liver, or multivisceral transplants were excluded from analysis. Data on demographics, donor, liver disease, comorbidities including cardiovascular conditions, arterial patency, and survival outcomes were analyzed. The study was approved by the local ethic committee (2016-01889).
DEFINITION OF ARTERIAL PATENCY AFTER LT
At our institution, Doppler sonography of inflow and outflow of hepatic vessels was routinely performed on the first and second posttransplant day and whenever indicated by clinical or laboratory findings. In the presence of abnormal findings, arterial angiography was performed in all patients to confirm or rule out arterial occlusion.
Primary patency which was the primary endpoint of this study was defined as time from transplantation or arterial anastomosis to occlusion or last patency followup. Arterial occlusion was defined either as total (hepatic artery thrombosis [HAT]) or partial occlusion (eg, stenosis, dissection, kinking) requiring intervention. Primary-assisted patency was defined as time from transplantation or arterial anastomosis to stenosis or last patency follow-up including intervention (surgical or endovascular) for partial occlusion to maintain patency. Secondary patency was defined as time from transplantation or arterial anastomosis to occlusion or last patency follow-up including intervention (surgical or endovascular) for total occlusion to re-establish patency. The definitions of primary, primary-assisted, and secondary patency of the hepatic artery are based on Reporting Standards of the Society for Vascular Surgery and the American Association for Vascular Surgery. (14) We defined early occlusion when it occurred within 30 days after LT and overall occlusion when it occurred during the complete observation period after LT.
ASSESSMENT OF RECIPIENT DISEASE
Acute morbidity conditions reflecting the severity of liver disease included laboratory Model for End-Stage Liver Disease (MELD) score at time of LT, life support treatment (respiratory failure requiring ventilation and/or renal failure requiring renal replacement therapy), and intensive care unit (ICU) treatment prior LT. In addition, data on liver-specific cancer (hepatocellular, cholangiocellular carcinoma) were collected. Chronic morbidity included cardiovascular risk variables described below.
CARDIOVASCULAR RISK EVALUATION
In order to investigate the potential impact of vascular conditions on posttransplant arterial occlusion, all recipients were screened for metabolic and cardiovascular disorders. This included the variables coronary artery disease, abdominal aortic calcifications, dyslipidemia, and serum lipid status including low-density lipoprotein (LDL)/high-density lipoprotein (HDL) ratio and arteriogenic index of plasma, (15) hypertension, diabetes mellitus, metabolic syndrome, and use of aspirin prior transplantation. Arteriogenic index of plasma has been used as a predictor of atherosclerosis and presents the logarithmically transformed ratio of triglyceride and HDL cholesterol in plasma. (16) Metabolic syndrome was defined according to the World Health Organization's clinical criteria with the constellation of glucose intolerance (type 2 diabetes, impaired glucose tolerance, or impaired fasting glycemia), insulin resistance, central obesity, dyslipidemia, and hypertension. (17, 18) Abdominal aortic calcifications have been proposed as markers of atherosclerotic disease and predictors of vascularassociated morbidity and mortality and were assessed on available computed tomography (CT) scans prior to LT using the proposed grading system of aortic calcifications. (19) POSTTRANSPLANT OUTCOME MEASURES
The study included an arterial patency analysis in which the primary endpoint was primary patency of the hepatic artery after LT. In addition, primaryassisted and secondary patency after LT was analyzed.
Secondary outcome measures included intraoperative flow of the reconstructed hepatic artery, primary allograft function, postoperative complications, unplanned reoperation, lengths of ICU and hospital stay, readmission within 90 days after LT, as well as graft and patient survival. Intraoperative flow of the reconstructed hepatic artery was measured using Doppler sonography (Medistim, Veriq). Primary allograft function was classified in normal allograft function (NAF), early allograft dysfunction (EAD), and primary nonfunction (PNF). EAD was defined according to Olthoff et al. (20) Patients requiring retransplantation or dying within the first 7 days were classified as PNF. (21) Patients who did not fit into 1 of both groups were classified as NAF. Postoperative complications were ranked using the Clavien-Dindo classification, (22) and overall in-hospital morbidity was assessed by the comprehensive complication index (CCI). (23) Lengths of ICU and hospital stay were measured from LT to discharge or death. Graft survival was measured from transplantation to last follow-up, retransplantation, or death. Patient survival was measured from transplantation to last follow-up or death.
STATISTICAL ANALYSIS
Data are reported as mean (standard deviation), median (interquartile range [IQR]), and n (%), where appropriate. Receiver operating characteristic curve analysis was performed to identify the ideal cutoff point for continuous variables. Continuous variables were compared with the Student t, Mann-Whitney U, 1-way analysis of variance, and Kruskal-Wallis tests, where appropriate. Differences among proportions derived from categorical data were compared using the Fisher's exact or the Pearson v 2 tests, where appropriate. Survival or time-to-event analysis was performed using Kaplan-Meier curves, where patients lost to follow-up or follow-up time ended were censored. Differences in survival or time to event were compared using the log-rank test. All P values in the univariate analysis were 2-sided and considered statistically significant if P 0.05. The backward stepwise logistic regression model was used to estimate the odds ratio (OR) and 95% confidence interval (CI) and to identify independent predictors for early arterial occlusion. Similarly, a Cox regression analysis was performed to identify independent predictors of overall arterial occlusion. Statistical analysis was performed using SPSS, version 23 for Mac (IBM, Armonk, NY), R, 
Results
STUDY POPULATION
During the study period, a total of 404 consecutive LTs were performed. According to the exclusion criteria, 43 patients were excluded from analysis due to living donor LT (n 5 37), split LT (n 5 3), multivisceral transplantation (n 5 1), and intraoperative death (n 5 2). The final outcome analysis was performed in 361 cadaveric LTs with a median follow-up time of 46 months.
The median recipient age was 56 years (IQR, 49-62 years), and the majority of patients were male (n 5 256, 71%). At the time of LT, the median laboratory MELD score was 20 (IQR, 10-31) and 88 (24%) patients were on life support treatment (intubation, on dialysis) before LT. The majority of recipients (n 5 323, 90%) received organs from DBD donors and only 11% of organs were retrieved from DCD donors ( Table 1) . A total of 47 patients (13%) underwent liver retransplantation. Further characteristics of the study population are presented in Table 2 .
AR TECHNIQUE
Arterial revascularization without additional reconstruction was performed in 279 (77%), back-table AR in 53 (15%), and AHC in 29 (8%) patients. Unsurprisingly, the AA group had predominantly type 1 donor arterial anatomy (90%), whereas the AR group had donor arterial anatomy type 1 in 21%, type 2 in 23%, type 3 in 41%, and type 4 in 15% of patients (Table 1) .
AHCs (n 5 29) were only performed as a rescue procedure when regular arterial graft revascularization was not feasible or failed during LT. This was primarily an intraoperative decision. Detailed reasons behind pursuing AHC were low hepatic artery flow (n 5 13), intima dissection of the recipient hepatic artery (n 5 5), HAT (n 5 3), hepatic artery too short (n 5 3), pronounced varices around the hepatic artery (n 5 1), and already existing conduit in retransplantation (n 5 4). In AHC, the donor iliac artery graft was used and anastomosed between the recipient's infrarenal (n 5 27) or supraceliac (n 5 2) aorta and the donor celiac trunk or hepatic artery.
PATIENT AND DISEASE CHARACTERISTICS
Among all reconstruction groups, there was no significant differences in donor and recipient demographics (age, sex distribution, and body mass index [BMI]), as well as the severity of the recipient's liver disease reflected by laboratory MELD score and proportion of patients on life support treatment before LT ( Table 2 ). However, the AHC group had a significantly higher proportion of patients who underwent liver retransplantation (41% versus 17% versus 9%). Although the AHC group had a higher proportion of patients with dyslipidemia (P 5 0.09) and pretransplant aspirin treatment (P 5 0.04), other cardiovascular risk factors, lipid status parameters, and grading of aortal calcifications were not significantly different between the groups (Table 2) .
INTRAOPERATIVE OUTCOME
Operation time was significantly longer for the AHC group compared with the AA and AR groups (Table  3) . Cold ischemia times were not significantly different among all 3 groups. The AHC group had the highest median intraoperative flow rate compared with the AA and AR groups (275 versus 250 versus 200 mL/ minute; P 5 0.02; Table 3 ).
AR AND POSTTRANSPLANT OUTCOME
We observed in the AHC group the highest incidence of EAD (45%) and PNF (10%) gradually followed by the AR group (36% and 6%) and AA group (32% and 3%). Consecutively, the AHC group had a significantly longer length of ICU stay and higher overall morbidity assessed by the CCI, whereas hospital stay and readmission rate within 90 days were comparable among all groups (Table 4) .
One-year primary patency rates of AA, AR, and AHC were 97%, 88%, and 74%, respectively (Fig.  1A) . One-year primary assisted patency and secondary patency rates of AA, AR, and AHC were 64%, 50%, and 50% and 62%, 71%, and 63%. Similar to the pattern of primary patency, graft and patient survival was best for the AA group, intermediate for the AR group, and inferior for the AHC group (Fig. 1B,C) .
EVENTS OF ARTERIAL OCCLUSION AND RELATED INTERVENTIONS
Overall, 43 (12%) recipients had an occlusive event with total occlusion in 28 patients and partial occlusion in 15 patients (Table 5 ). Early (30 days) and longterm (at 1 year) hepatic artery occlusion rates for AA, AR, and AHC were 3.6%, 11%, and 21% (P < 0.001) and 8%, 19%, and 35% (P < 0.001), respectively. Univariate analysis revealed that the grade of aortic calcifications, dyslipidemia, number of arterial anastomosis, use of AHC, length of ICU stay, impaired initial allograft function, and postoperative complications were associated with early occlusion (Supporting Table 1 ). EAD occurred more often at a rate of 59% in patients with an early occlusive event.
A total of 13 patients with occlusion required surgical intervention (redo anastomosis, n 5 9; redo conduit, n 5 3; retransplantation, n 5 1), whereas the majority of patients (70%) were nonoperatively managed by interventional radiology. Nonoperative management was more frequently applied in partial versus total occlusion (93% versus 57%). In 10 occlusive events, no intervention, except angiography, was necessary due to reestablished arterial collateralization. Of those, 9 patients were diagnosed within 1 year after transplantation and 1 within 3 years after LT. Only 1 patient needed retransplantation. Overall, 6 patients required retransplantation due to unsuccessful revascularization (14%), and 9 patients died due to hepatic artery occlusion (21%).
INDEPENDENT RISK FACTORS FOR ARTERIAL OCCLUSION AND PREDICTORS FOR NEED OF CONDUIT
Multivariate analysis identified both AHC and AR as independent risk factors for early and overall occlusion ( Fig. 2A,B) . Aside from dyslipidemia, neither graft type, severity of liver disease (MELD score, life support treatment) nor metabolic or cardiovascular factors were independently associated with occlusion. Although AHCs were more frequently used in the retransplantation setting, the use of a conduit remained to be independently associated with early and overall occlusion. In order to figure out whether these findings might be influenced by the more frequent use of AHC in the setting of retransplantation, we performed an additional multivariate analysis in the cohort of primary LT only (n 5 314). The analysis confirmed comparable risk factors for early and overall occlusion demonstrating that the type of reconstruction appears also to be the most important predictor for arterial occlusion in the primary LT setting (Supporting Table 2 ). Moreover, a multivariate analysis identified retransplantation and aspirin treatment at time of admission before LT as independent predictors for the requirement of AHC (Fig. 2C) .
TRANSARTERIAL CHEMOEMBOLIZATION AND ARTERIAL OCCLUSION
Out of 134 patients with hepatocellular carcinoma (HCC), 112 (84%) had transarterial chemoembolization (TACE) treatment before LT. Although the comparison of TACE across the groups was not different (Table 2) , recipients with HCC were more likely to undergo AR (51%, P 5 0.01). Therefore, we explored whether TACE/HCC and AR have a synergistic effect on the development of occlusion. We identified 21 patients with HCC and AR with TACE and 6 patients without TACE showing a 28% versus 0% occlusion rate. Although included in the multivariate analysis, TACE failed to be an independent predictor for arterial occlusion for either early versus overall occlusion or entire versus primary LT cohorts ( Fig. 2A,B ; Supporting Table 2 ).
FIG. 1.
Kaplan-Meier plots of (A) primary patency (1-and 5-year patency rate for AA, 91% and 89%; AR, 81% and 81%; and AHC, 65% and 54%, respectively); (B) graft survival (1-and 5-year graft survival rate for AA, 83% and 70%; AR, 74% and 69%; and AHC, 59% and 50%, respectively); and (C) patient overall survival (1-and 5-year patient survival rate for AA, 86% and 74%; AR, 77% and 67%; and AHC, 65% and 61%).
Discussion
The main finding of the present study was that primary arterial patency after LT is predominantly determined by the type of vascular reconstruction rather than patient or disease characteristics. One-year primary patency rates were highest in the AA group followed by the AR and AHC group. Revascularization requiring AR or the use of an AHC were independent risk factors for hepatic artery occlusion, whereas neither recipients' cardiovascular risk nor severity of preoperative liver disease had any significant impact on hepatic arterial occlusion rates. This is, to the best of our knowledge, the first cohort study analyzing hepatic arterial patency rates as well as patient and graft survival comparing 3 different types of arterial revascularization in cadaveric adult LT. Using the definitions of the Committee on Reporting Standards of the Society for Vascular Surgery and the American Association for Vascular Surgery, (14) we provide a standardized report on primary, primary-assisted, and secondary patency rates. Although the majority of studies focus exclusively on HAT, (24, 25) the present study was designed to look at both total and partial occlusion. Although total occlusion is mainly caused by HAT, partial occlusion might be related to various etiologies including anastomotic stenosis/stricture, dissection of the arterial wall, kinking, or partial thrombosis. The incidence of hepatic arterial occlusion by HAT in LT ranges between 4% and 9% in the literature, (8) (9) (10) with a retransplantation rate of over 50%. (2, 6) In our cohort, the overall hepatic artery occlusion rate was 12% with 8% accounting for HAT that compares to the reported figures in the literature. In accordance with other reports, (26, 27) we found the highest occlusion rate in the AHC group followed by the AR group. Another important finding of our study was the observation that interventions for partial occlusion did not lead to higher patency (primaryassisted patency). Although total occlusion of the hepatic artery is effectively solved by intervention in most patients (secondary patency), the median time to arterial event is more than twice as long for partial occlusion compared with total occlusion (Table 5) .
Cardiovascular-associated pathologies can lead to atherosclerotic disease with formation of calcified plaques in arteries of donors and recipients, which might compromise arterial patency of hepatic inflow after LT. We, therefore, investigated the impact of cardiovascular-associated pathologies in donors and recipients on arterial patency after LT (Tables 1 and  2 ). Donors were screened for history of hypertension, diabetes mellitus, and cardiovascular disease while the risk analysis of recipients included cardiovascular risk factors, lipid metabolism, and characteristic parameters of atherosclerosis such as arteriogenic index and aortic calcifications. Although donor risk factors had no impact on arterial patency in our study, there is reported evidence that the presence of calcified plaques in hepatic arteries especially in elderly donors is associated with arterial complications after LT. (28) To the best of our knowledge, this is also the first study looking at calcifications of the abdominal aorta in recipients as a marker of atherosclerotic disease. Although each NOTE: Data are given as n (%) or median (IQR). *Only angiography.
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FIG. 2.
Multivariate analysis for (A) early occlusion, (B) overall occlusion, and (C) need for conduit. OR and HR plots are presented for risk factors of (A) early and (B) overall occlusion as well as (C) predicting variables for need of conduits.
recipient had pretransplant abdominal imaging by CT and/or magnetic resonance imaging (MRI) scan, calcified plaques can only be assessed by CT scans. However, this was possible in the majority of our patients because 85% of all recipients in our cohort had CT imaging before LT. The presence of aortic calcifications was a significant risk for early arterial occlusion in our univariate analysis, but this variable was not included in the multivariate analysis due to missing data on calcification in 15% of recipients who had only pretransplant MRI scanning. Among all screened cardiovascular-associated risk factors, dyslipidemia was the only independent predictor for early occlusion ( Fig. 2A) . The underlying mechanism of this finding is still not well understood. However, some data indicate that high levels of blood lipids are associated with an increased coagulation activity (29, 30) and that hypercoagulation occurs more frequently in patients with metabolic syndrome. (31) The central finding of the present study was that the type of performed revascularization technique was the most important denominator for primary patency of the hepatic artery. This was true for early as well as overall hepatic artery occlusion when potentially confounding factors such as retransplantation, preoperative life support treatment, high MELD, and advanced recipient age were adjusted in the analysis. The finding of the importance of the arterial revascularization technique appears robust because it applies not only to the entire cohort but also to the setting of primary LT. Besides regular arterial revascularization, ARs are performed in up to 20% due to aberrant hepatic arteries, (32, 33) and AHCs are performed in approximately 10% of all LTs. (34, 35) These data in the literature go along with the observed incidence of AR at 14% and AHC at 9% in our study. However, the need of AHC or AR cannot be neglected, but so far, a consensus on technique as well as guidelines on prophylactic antiaggregation treatment has not been established. On the basis of the identified independent risk factors in our study, a special detection protocol for occlusion in high-risk cardiovascular patients appears not strictly necessary. Our implemented policy relies on Doppler sonography of inflow and outflow of hepatic vessels on the first and second posttransplant day and afterward whenever indicated by suspicious clinical or laboratory findings.
Although some authors did not find differences in patency rates among various AR techniques, (36) the majority of studies including our analysis suggested that complex arterial back-table reconstruction (37) and use of AHC (7, 8, 26) were associated with a greater risk of developing arterial complications including HAT. A recently published study revealed that not only donor arterial variation requiring reconstruction but also a long graft artery was a risk factor for early occlusion. (38) In order to reduce adverse arterial events, the authors of this study recommended that short artery grafts should be preferably used and redundant length of arteries needs to be avoided. When this finding might be applicable to AHC, a supraceliac placement might be associated with better patency outcome due to shorter conduit length than using longer infrarenally placed grafts. However, this assumption is only of speculative nature due to lacking data in the literature. Another strategy to reduce arterial occlusion might be the use of prophylactic antiaggregation treatment after LT. Although 1 center routinely uses aspirin prophylaxis after LT for AHC, (11) evidence-based data or studies are lacking for such approach. Overlooking our entire cohort, only 4% of patients had an antiaggregation therapy at the time of discharge.
The role of TACE and postoperative complications for the risk of HAT has been continuously debated as a hot topic in the liver transplant community. There is evidence that TACE causes mechanical damage to the hepatic artery wall (39) (40) (41) making the artery prone to arterial complications including HAT. Although TACE was associated with a higher occlusion rate in the AR/HCC subgroup in the present study, our multivariate analysis failed to identify TACE as a risk factor in either the entire or the primary LT cohort. A very recently published systematic review and metaanalysis demonstrated that TACE was associated with arterial complications but not with HAT alone after LT. (42) However, the vast majority of the individual studies in this meta-analysis failed statistical significance of an association between TACE and arterial complications, which was the case in our study as well. In terms of postoperative complications, we observed, as have others, (5, 6, 8, 38) higher morbidity for patients with arterial complications. However, complications might trigger HAT, but it is often in the end not clear whether a complication triggered HAT or HAT contributed to the occurrence of complications.
The higher hepatic artery occlusion rate in the AHC and AR group resulted in inferior patient and graft survival, which is in line with the current literature. (8, 35) Furthermore, the AHC group had somewhat expectantly the highest incidence of EAD and PNF, which might be potentially explained by the higher occlusion rate or the higher incidence of retransplantations in this group. In our cohort, 14% of recipients required retransplantation due to hepatic artery occlusion. Duffy et al. reported retransplantation rates of 17% for early and up to 50% for late hepatic artery occlusion. (8) Consequently, the 5-year graft survival in recipients with AHCs was impaired and was only at 49%. In contrast, the study by Soliman et al. showed similar 5-year graft and patient survival for the AA and AR groups although AR was also associated with a higher rate of HAT. (37) Although many studies report on the outcome of AHCs, (11, 26, 35) none analyzed predicting factors for the need of AHC. We, therefore, included in our study a multivariate analysis looking at independent predictors and identified retransplantation and medication with aspirin at admission as independent predictors for the need of AHC (Fig. 2C) . Notably, AHCs are rescue options when regular AR cannot be performed. Especially in liver retransplantation, regular arterial inflow reconstruction is often not possible or retransplantation is even performed due to arterial complications including HAT. (6, 12, 26) Another limiting condition for an unusable recipient hepatic artery might be related to cardiovascular-associated pathologies including atherosclerosis. Aspirin treatment at admission might be a surrogate marker for such pathologies and might therefore indicate a higher likelihood for failed hepatic artery reconstruction. This might be a potential explanation why patients with aspirin treatment at admission have a higher chance to undergo LT with AHC.
In our cohort, we also identified 10 patients with HAT, where no further therapy was needed. Nine of them had a totally occluded and 1 had a partially occluded hepatic artery. We suppose that imagingproven collateral transformation maintained the good liver function. Garc ıa Bernardo et al. described the development of collaterals after HAT in a series of 18 patients, where only 1 patient with diagnosed collaterals needed retransplantation. (43) The superior survival of patients with HAT who develop collaterals was also reported by Viveiros et al. (44) The authors of this study found an overall survival rate after 5 years of >80% in HAT patients with collaterals compared with 60% in patients without collaterals.
The strength of this study is related to the detailed analysis of the AR types, cardiovascular risk, and their associated outcomes, which is rarely reported. Moreover, abdominal aortic calcification as a marker of atherosclerotic disease and as a predictor of vascularassociated morbidity and mortality were included in the occlusion risk analysis. In addition, this study analyzed for the first time predicting factors for the need of an AHC. However, our study is also associated with certain limitations that are related to the retrospective study design, the selection bias for which patient received a back-table AR or an AHC, the era bias with patient data collected during a 9-year period, and the diagnostic bias, which arises from the lack of routine screening for HAT and stenosis beyond the initial hospital stay. The issue related to the diagnostic bias is that asymptomatic hepatic artery occlusion occurring late in the posttransplant course may have been undetected, and their true incidence might be even higher as reported in this study. To control and minimize potential drawbacks, a multivariate analysis was applied to control multiple risk factors and confounders.
In conclusion, arterial patency is primarily determined by the type of vascular reconstruction rather than recipients or disease characteristics. Although transplant surgeons often have no alternative options to ARs and AHCs, both reconstruction techniques, especially AHCs, harbor an elevated risk for occlusion, which always needs to be considered during the posttransplant course and follow-up. Whether antiaggregative or anticoagulative prophylactic treatment might be protective for arterial patency is currently not clear and should be urgently explored in future studies.
